GlassVC
Novartis Venture Fund

Novartis Venture Fund

Corporate venture firm · Founded 1996 · Cambridge, MA · Boston ↗

Novartis's corporate venture fund, active since 1996, investing in biotechnology and biopharmaceutical companies across North America and Europe from teams in Cambridge, Massachusetts and Basel, Switzerland.

Tier 2Basis: AUM approximately $750M per the fund's own website falls in the $500M-$2B Tier 3 band.

Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.

This profile is unclaimed. Built from public sources. If you're a partner or employee at Novartis Venture Fund, you can claim it.

Claim this profileHow claiming works

Key numbers

Assets under management

$750M

Latest fund

Not publicly disclosed

LAST CHECKED NOV 2026

Funds

No public record

LAST CHECKED NOV 2026

Check size

$5M–$10M

Stages

SeedSeries ASeries B

Sectors

biotechnologybiopharmaceuticalslife sciences

FIGURES ARE AS PUBLISHED IN THE CATALOG RECORD 1 · PER-FIGURE AS-OF DATES ARE NOT YET IN THE CATALOG

Track record

Outcomes are recorded from public sources and attributed to the firm, not to individual partners. Shutdowns and write-offs are an ordinary part of venture investing; inclusion here is a record, not a judgment.

Hits

  • Bicycle Therapeuticsipo

    Listed on NVF's own IPO-exits page: Bicycle Therapeutics completed its initial public offering (NASDAQ: BCYC) in 2019. NVF's stated investment range is USD 5-10M, with up to USD 25M allocated per company over its life.

    Source: nvfund.com

Misses

Track record

No outcomes recorded yet from public sources.

Partners 2

Reputation 2

No reputation score — basis not established for this firm.

Contact

Published sources only

Published contact

Published sources only

GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.

SOURCE: FIRM WEBSITE, AS PUBLISHED 2

What founders say

Founder-submitted · Verified identity and relationship

No founder reviews yet

Be the first founder to share your experience with Novartis Venture Fund. Reviews come from founders whose identity and relationship have been verified.

Write the first review

Methodology

Tier basis — AUM approximately $750M per the fund's own website falls in the $500M-$2B Tier 3 band. Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.

Figures are shown as published; conflicting figures are never averaged. Review dimension scores appear only once three founders have reviewed this firm; profiles below that threshold do not appear in rated lists.

The catalog does not yet carry per-figure citations or as-of dates: every figure on this page traces to the catalog record listed below, and that limit is stated rather than papered over. Corrections with a source: Suggest a correction.

Source record 2

  1. [1]

    DATABASE · GlassVC catalog — Catalog record for Novartis Venture Fund — provenance: GlassVC extended catalog, November 2026

    CATALOG SOURCE FIELD · LAST CHECKED NOV 2026

    ↩ cites: AUM · Check size · Founded · HQ · Stages · Sectors · Track record · Reputation

  2. [2]

    FIRM SITE · Novartis Venture Fund — Firm website, as published by the firm

    LAST CHECKED NOV 2026 ↗

    ↩ cites: Website

PROFILE BUILT FROM PUBLIC SOURCES · 2 CATALOG SOURCES · LAST CHECKED NOV 2026